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Case Report
Subconjunctival Bevacizumab as an Adjunct to Trabeculectomy 
in Eyes with Refractory Glaucoma: A Case Series
Jin Young Choi, Jaewan Choi, Yeon-Deok Kim
HanGil Eye Hospital, Incheon, Korea
This prospective observational case series study included 6 eyes of 6 consecutive glaucomatous patients. Each pa-
tient underwent trabeculectomy with mitomycin C, and received a 1.25 mg of subconjunctival bevacizumab injection 
at completion of the trabeculectomy. Study eyes included two with neovascular glaucoma, three with uveitic glauco-
ma, and one with secondary glaucoma following vitrectomy. All eyes had undergone failed glaucoma laser/surgical 
treatment or an intraocular surgical procedure. Intraocular pressure (IOP) at the following postoperative visits: pre-
operative, 1 week, 1 month, 2 months, 3 months, and 6 months, was measured. We also evaluated postoperative 
bleb findings and complications. IOP measured at each visit was 37.5±14.4 mmHg, 6.2±3.4 mmHg, 8.3±7.2 mmHg, 
12.0±4.4 mmHg, 10.8±3.1 mmHg, and 12.2±3.3 mmHg, respectively, for each visit. All eyes had functioning blebs 
with normal IOP at postoperative 6 months with no additional IOP-lowering medication. 
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Recent advances in understanding the mechanism of an-
giogenesis have facilitated the development of new treatment 
options for neovascular ocular diseases. Neovascularization 
(NV) occurs as a result of angiogenic stimuli, including the 
vascular endothelial growth factor (VEGF) [1]. Bevacizumab 
(Avastin
®; Genentech, South San Francisco, CA, USA) is a 
recombinant humanized monoclonal immunoglobulin G1 an-
tibody directed against VEGF [2]. Bevacizumab was origi-
nally granted approval as a first-line therapy in metastatic col-
orectal cancer [3]. In the field of ophthalmology, encouraging 
data from clinical studies involving intravitreal bevacizumab 
injection to treat age-related macular degeneration, severe 
proliferative diabetic retinopathy, and iris neovascularization 
have led to trials involving different routes of bevacizumab 
administration to treat various eye disorders [4-6]. Topical or 
subconjunctival application of bevacizumab was found to be 
effective for inhibiting corneal neovascularization in both an 
experimental rat model and in humans [7, 8].
Modulating the wound healing process to lessen scar 
formation around the scleral flap plays a crucial role in 
the success of glaucoma filtering surgery. The use of anti-
metabolites, such as mitomycin C (MMC) or 5-fluorouracil 
(5-FU), has been widely advocated for trabeculectomy to 
modulate fibroblast proliferation. A recent pathological 
study demonstrated that neutralization of VEGF reduced 
vascularity and decreased scar formation during wound 
healing, showing that VEGF strongly influenced scar tissue 
formation [9,  10]. Jonas et al. [11] also showed the efficacy 
of intravitreal bevacizumab injection as a supplementary 
procedure in standard trabeculectomy for eyes showing 
neovascularization or persistent macular edema.
  Although 
encouraging, this report was limited in that the main purpose 
of intravitreal bevacizumab administration was to control 
accompanying macular edema or iris neovascularization. 
Recently, Grewal et al. [12]
  showed that 11 of 12 eyes 
(92%) that underwent trabeculectomy exhibited successful 
intraocular pressure (IOP) control with subconjunctival 
bevacizumab injection. However, none of the eyes in that 
study had a history of laser or surgical intervention. We 
investigated the effect of subconjunctival bevacizumab 
administration as an adjunct treatment to trabeculectomy 
in eyes with prior laser or surgical treatment.Korean J Ophthalmol Vol.24, No.1, 2010
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Fig. 1. Intraocular pressure (IOP) changes following trabeculec-
tomy plus subconjunctival bevacizumab administration.
Case Reports
A sample of eligible patients was consecutively iden-
tified for inclusion in the study from September 2007 to 
January 2008. Patients with uncontrolled IOP (more than 
21 mmHg) on maximal tolerable medical treatment were 
included. The study eyes consisted of two with neo-
vascular glaucoma (NVG), three with uveitic glaucoma, 
and one with secondary glaucoma following retinal de-
tachment surgery. All six eyes had a history of failed 
glaucoma laser treatment or an intraocular surgical proce-
dure (two trabeculectomy, one Ahmed glaucoma drainage 
implantation, two selective laser trabeculoplasty (SLT), 
and one multiple intravitreal injections), and two eyes had 
previous pars plana vitrectomy (PPV) among them. Data 
collected for analysis included patient demographics, pre-
vious ocular or systemic history, slit-lamp evaluation, IOP 
measurement, postoperative bleb findings, and complications 
for six months postoperatively. This study was approved by 
the Institutional Review Board of the HanGil Eye Hospital. 
Informed patient consent was obtained for the off-label use 
of bevacizumab from all patients, and all procedures con-
formed to the tenets of the Declaration of Helsinki.
Fornix- or limbus-based trabeculectomy was performed. 
Conjunctiva was incised at about 1 mm from the limbus 
for the fornix-based trabeculectomy, and at about 8 mm 
from the limbus for the limbus-based trabeculectomy. 
Tenon’s capsule was gently dissected between the capsule 
and episclera. A lamellar scleral flap was made in a triangular 
shape, a 0.04% MMC-soaked sponge was applied for 2 
minutes beneath the conjunctival and scleral flap, the tra-
becular and deep peripheral corneal tissues were excised, 
a peripheral iridectomy was performed, the scleral flap 
was re-fixed using 2 or 3 stitches of 10-0 nylon interrupted 
sutures, and the conjunctiva was closed water-tight using a 
9-0 Vicryl continuous suture for both the fornix- and the 
limbus-based trabeculectomy. Upon completion of surgery, 
0.2 mL (1.25 mg) bevacizumab was injected subconjuncti- 
vally on the opposite side of the bleb. The eye was treated 
with topical antibiotics (0.5% levofloxacin, Cravit
®; Santen, 
Osaka, Japan), a steroid (1% prednisolone acetate, Pred Forte
®; 
Allergan, Irvine, CA, USA), and cycloplegic eye drops (1% 
atropine sulfate, Ocu-tropine
®; Samil Pharmaceuticals, 
Seoul, Korea) postoperatively for about a month. 
The diagnosis, demographics, preoperative status, and 
surgical details of each patient are briefly summarized in 
Table 1. Study eyes included two with neovascular glaucoma, 
three with uveitic glaucoma, and one with secondary glaucoma 
following vitrectomy. All eyes had undergone failed glau-
coma laser/surgical treatment or an intraocular surgical 
procedure. As shown in Fig. 1, the IOP measured preoperatively 
was 37.5±14.4 mmHg; the IOP measured at each visit 1 week, 
1 month, 2 months, 3 months, and 6 months postoperatively 
was.6.2±3.4 mmHg, 8.3±7.2 mmHg, 12.0±4.4 mmHg, 
10.8±3.1 mmHg, and 12.2±3.3 mmHg, respectively.
Case 1
A 75-year-old woman complained of decreased vision 
and ocular pain in the left eye. The patient was diagnosed 
with NVG associated with proliferative diabetic retinop-
athy and was referred by a retinal specialist to our glaucoma 
clinic. Slit lamp findings included rubeosis iridis, NV of the 
angles, and severely inflamed conjunctiva, even though 
the eye had previously undergone multiple sessions of 
panretinal photocoagulation (PRP), intravitreal triamcinolone 
acetate (IVTA) injections, and an intravitreal bevacizumab 
injection. The best-corrected visual acuity (BCVA) was 
for hand movement. IOP had ranged from 56 to 66 
mmHg over a few weeks. Limbus-based trabeculectomy 
was performed, and IOP measured at postoperative 1 
week, 1 month, 2 months, 3 months, and 6 months was 
10, 22, 18, 12, and 15 mmHg, respectively. Laser suture 
lysis was performed 4 weeks after surgery, and digital 
eyeball massage was recommended. A localized avascular 
bleb with moderate height was observed six months post-
operatively, but the BCVA did not change. No addi-
tional IOP-lowering medication was required (Fig. 2A). 
Case 2
A 63-year-old male patient visited our glaucoma clinic 
diagnosed with NVG associated with ocular ischemic 
syndrome in the right eye. The eye had undergone trabe-
culectomy twice at another hospital. Slit lamp findings 
included pseudoexfoliative material deposition on the 
lens and the pupillary margin, rubeosis iridis and NV of 
the angles. The patient had ischemic changes on the retina, 
and PRP was performed. IOP was not controlled with 
maximal tolerable medical treatment (MTMT) including 
oral acetazolamide. BCVA was 20/30, and IOP ranged 
from 28 to 38 mmHg. Optic disc evaluation revealed increased 
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Table 1. Summary of patients treated with subconjunctival bevacizumab as an adjunct to trabeculectomy
Case Diagnosis Age Gender Eye Previous ocular 













1 NVG in eye 
with PDR





66 16 Yes Yes 0 TRAB only
Uneventful
2N V G  i n  e y e  
with OIS PEX




24 10 Yes No 0 TRAB only








27 13 No No 0 TRAB only
Viscoelastics injection due to 
shallow anterior chamber 
(post-op 1 wk) 
Cataract surgery (post-op 8 wk)
4 Uveitic 
glaucoma


























30 12 No No 0 TRAB only
Wound revision due to hypotony 
and persisted choroidal effusion 
(post-op 4 wk)
TRAB=trabeculectomy; IOP=intraocular pressure; LSL=laser suture lysis; MED=anti-glaucomatous medication; NVG=neovascular glau-
coma; PDR=proliferative diabetic retinopathy; PRP=panretinal photocoagulation; IVTA=intravitreal triamcinolone acetate; IV=intra-
vitreal; OIS=ocular ischemic syndrome; PEX= pseudoexfoliation; TA=triamcinolone acetate; PPV=pars plana vitrectomy; GDDI=glauco-
ma drainage device implantation; RD=retinal detachment; EB=encircling buckle; SLT=selective laser trabeculoplasty; 5-FU=5-fluorouracil.
cup-to-disc (C/D) ratio of 0.9, with inferior neuroretinal 
rim loss. Fornix-based trabeculectomy was performed. IOP 
measured at postoperative 1 week, 1 month, 2 months, 3 months, 
and 6 months was 5, 7, 14, 11, and 8 mmHg, respectively. 
Microleakage of the conjunctival wound was noted 
within the first 3 days after surgery, but healed sponta-
neously without intervention. Laser suture lysis was done 
at postoperative 3 weeks. A localized avascular bleb with 
moderate elevation was noted. No additional IOP-lowering 
medication was required (Fig. 2B).
Case 3 
A 40-year-old man was referred to our glaucoma clinic 
diagnosed with panuveitic glaucoma in the left eye. The 
patient was on MTMT, including oral prednisolone and 
cyclosporin. The eye had previously undergone multiple 
subtenon injections of triamcinolone acetate and an SLT 
procedure. The IOP was 27 mmHg, and the BCVA was 
20/30. Optic disc evaluation revealed a C/D ratio of 0.7, 
with inferior neuroretinal rim thinning. Serial visual 
field examination revealed worsening of the visual field 
over several months. Fornix-based trabeculectomy was 
performed. A shallow anterior chamber was noted at 
postoperative 1 week, and viscoelastic material (Healon GV
®; 
Advanced Medical Optics, Santa Ana, CA, USA) was 
injected into the anterior chamber. IOP measured at 
postoperative 1 week, 1 month, 2 months, 3 months, and 
6 months was 4, 2, 8, 11, and 14 mmHg, respectively. 
Cataract surgery was performed 2 months postoperatively 
due to a progressing posterior subcapsular cataract. A lo-
calized avascular bleb with moderate elevation was noted 
upon final follow-up. The final BCVA was 20/25. No 
additional IOP-lowering medication was required (Fig. 2C).
Case 4 
A 30-year-old man presented with panuveitic glauco-
ma due to medically uncontrollable IOP in the right eye. 
The eye had previously undergone PPV and Ahmed 
glaucoma drainage device implantation two years prior. 
Multiple IVTA injections had been administered pre-
viously to control the uveitis. BCVA was 20/60 due to 
the cataract, and the IOP was 32 mmHg on MTMT. 
Optic disc evaluation revealed a C/D ratio of 0.8, with 
localized notching in the inferior neuroretinal rim. A 
dense arcuate scotoma was identified during a Humphrey 
visual field examination. Two-sited phacotrabeculectomy 
was performed. After the cataract was extracted and an 
intraocular lens (IOL) implanted, fornix-based trabecu-
lectomy was performed in the superior area. IOP meas-





Fig. 2. Representative postoperative slit lamp photographs. (A) Case 1. Localized avascular bleb formation in an eye with neovascular glauco-
ma (NVG). (B) Case 2. Localized bleb formation in the superior area in an eye with NVG. Note the presence of previously failed trabeculec-
tomy in the superonasal and superotemporal areas. (C) Case 3. Localized avascular bleb formation in an eye with uveitic glaucoma. (D) Case 
4. Diffuse and low bleb formation in an eye with uveitic glaucoma. Note the presence of a previously failed Ahmed drainage device in the super-
otemporal area. (E) Case 5. Localized avascular bleb formation in an eye with secondary glaucoma following retinal detachment surgery. Note 
the presence of the anchoring suture of the scleral buckle in the superotemporal subconjunctival area. (F) Case 6. Wound revision at 1 month 
after trabeculectomy in Case 6 revealed the absence of blood vessel formation or wound adhesion around the scleral flap.
and 6 months was 4, 5, 6, 5, and 8 mmHg, respectively. 
Diffuse and low bleb formation with no serious postoperative 
complications was noted during the follow-up period. Final 
BCVA was 20/30. No additional IOP-lowering medication 
was required (Fig. 2D). 
Case 5 
A 25-year-old man presented with increased IOP in the 
right eye. The patient had cataract extraction and an IOL 
implantation due to posterior subcapsular cataract one 
year ago. Subsequently, the eye underwent PPV with en-
circling buckling due to retinal detachment. The IOP was 
uncontrollable with MTMT after surgery. SLT had been 
repeated twice with at an interval of 1 month, but the effect 
was temporary. IOP was 32 mmHg at one month after the 
second SLT procedure, and the BCVA was 20/20. Slit 
lamp findings revealed normal open-angle on gonioscopy, 
and the C/D ratio was 0.6 with concentric cup enlargement. 
Limbus-based trabeculectomy was performed. During the JY Choi, et al. Subconjunctival Bevacizumab for Trabeculectomy
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surgery, the surgeon (JC) found that there was severe 
adhesion between the scleral buckle and overlying con-
junctiva behind the conjunctival incision line. IOP measured 
at postoperative 1 week, 1 month, 2 months, 3 months, and 
6 months was 11, 10, 14, 12, and 14 mmHg, respectively. 
A localized avascular bleb with moderate elevation was 
noted, but no serious postoperative complications were 
noted. The final BCVA was 20/20. No additional IOP- 
lowering medication was required (Fig. 2E).
Case 6 
A 73-year-old man with anterior uveitis had an IOP 
ranging from 17 to 30 mmHg in the left eye. Seven 
months ago, the patient underwent trabeculectomy in the 
superonasal area, following the bleb needling procedure 
with multiple 5-FU injections, upon uveitic glaucoma 
diagnosis. Worsening optic disc appearance and visual 
field changes were noted. The BCVA was 20/50. Fornix- 
based trabeculectomy was performed in the superotemporal 
area. Ocular hypotony with mild choroidal effusion per-
sisted for about one month after surgery. The bleb was 
diffuse and elevated with no conjunctival leakage. IOP 
measured at one week and one month was 3 and 4 
mmHg, respectively. Wound revision with additional suture 
of the scleral flap was performed at postoperative one month. 
During the revision procedure, the surgeon (JC) found that 
there was no blood vessel growth at either wound adhe-
sion around the scleral flap (Fig. 2F). IOP normalized to 
12 mmHg two months after the revision, and the choroi-
dal effusion resolved. Diffuse and low bleb with less 
marked vascularization was noted postoperatively. The 
final BCVA was 20/40. No additional IOP-lowering med-
ication was required.
Discussion
Conventional trabeculectomy is reported to be less suc-
cessful in eyes that have undergone failed glaucoma surgery 
or have a disease with poor prognosis (i.e. NVG or uveitic 
glaucoma), when compared to the eyes with primary disease, 
probably due to the aggressive wound healing process 
associated with excessive inflammation, adhesion, or angiog- 
enesis [13]. The low success rates of filtering surgery in 
these eyes have led to investigation of the adjunct trabe-
culectomy regimen. The use of antimetabolites (MMC or 
5-FU), amniotic membrane, or even photodynamic therapy 
has been advocated to enhance the surgical outcomes [14-16].
Angiogenesis, the process of new blood vessel for-
mation, is a key element in the proliferative phase of 
wound healing, supplying oxygen and nutrients to support 
the rapid growth of cell-mediated repair. Wilgus et al. [9] 
reported that VEGF promoted angiogenesis and scar for-
mation in early fetal skin and that a VEGF blockade in-
fluenced the organization of scar tissue. VEGF neutralization 
not only reduced the amount of scar tissue formed, but 
also improved the quality of the scar tissue that did form 
by shifting the collagen fibril distribution to a state more 
closely resembling normal skin in a mouse model. In a 
mouse model of bleomycin-induced pneumopathy, trans-
fection of the VEGF receptor (sflt-1) gene attenuated 
pulmonary fibrosis, suggesting that anti-VEGF treatment 
might be used as an antifibrotic therapy [17].
The most important cause of persistent IOP elevation 
after trabeculectomy is unduly marked or persistent in-
flammation, followed by deposition of fibrous tissue, 
which prevents the formation of an adequately draining 
bleb [18]. Modifying the wound healing process of the 
scleral flap upon trabeculectomy could enhance the surgi-
cal outcome. The topical and systemic applications of bev-
acizumab significantly inhibit both inflammation-induced 
angiogenesis and lymphangiogenesis in the cornea [19]. Re- 
ducing the amount of cytokines (e.g., fibroblast growth 
factor, VEGF) released from the vessels to the site of 
injury by blocking angiogenesis with bevacizumab may 
indirectly render the scleral flap less adherent to its 
original site during the immediate postoperative period, 
allowing more fluid to drain through the flap. Another 
possible explanation could be that bevacizumab itself 
acts on the scleral flap’s scar formation directly through 
fibroblast modulation [9]. Wu et al. [20]
  recently dem-
onstrated VEGF’s ability to induce keloid fibroblast pro-
liferation and suggested the presence of functional 
VEGF receptors on fibroblasts. The presence of VEGF 
receptors on fibroblasts is also supported by a study dem-
onstrating expression of VEGF receptor-2 in stromal cells 
during wound repair in vivo [21].
  A recent study showed 
that postoperative subconjunctival injection of bev-
acizumab was associated with improved trabeculectomy 
bleb survival in the rabbit model, suggesting bevacizumab 
may be a useful agent for improving the success rate and 
limiting scar tissue formation after trabeculectomy [22]. 
We found that the IOPs of all patients were within 
the normal range during the 6 month follow-up period. 
Postoperative complications in our study included early 
hypotony with IOP <5 mmHg (three eyes), cataract devel-
opment (one eye), and microleakage of the conjunctival 
wound (one eye). A bleb revision procedure was per-
formed one month after trabeculectomy in Case 6; neither 
vessel formation nor adhesion around the scleral flap 
was observed. Alternatively, relatively higher incidences 
of early hypotony I our series of patients and no vessel 
growth observed in Case 6 may hold clues to the potential 
of bevacizumab to modify the wound healing process 
following trabeculectomy. However, uncertain was the 
association of subconjunctivally injected bevacizumab with 
these surgical outcomes in our series of patients.
In a previous study, disintegration of the corneal epi-
thelium and progression of stromal thinning have been 
reported in an eye undergoing topical bevacizumab ap-Korean J Ophthalmol Vol.24, No.1, 2010
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plication for four weeks, suggesting that treatment may 
be related to adhesion between the epithelium and the 
basement membranes or inhibit the normal wound healing 
process [9]. While the inhibition of angiogenesis could 
play a beneficial role in the scleral flap healing process, 
also possible is that interrupted wound healing may dispose 
the conjunctival incision to postoperative leakage in trab- 
eculectomy. Precise surgical skill for watertight conjunctival 
closure is warranted if subconjunctival bevacizumab is used 
as an adjunct regimen to trabeculectomy. 
Our study has some limitations. Separating the effect of 
bevacizumab from that of concomitantly applied MMC 
on the wound healing process is difficult, as this study 
has taken the form of a small case series study design 
rather than a case-controlled one. Hence, suggesting that 
the high success rate in this study is wholly dedicated 
to the adjuvant use of subconjunctival bevacizumab would 
be inappropriate, as would be claiming that one drug has 
more potency in wound healing process than the others. 
The rather small number of subjects and short follow-up 
period for glaucoma are also major limitations. The efficacy 
and safety should be tested in the further case-controlled 
studies.
In summary, our report suggests that subconjunctival 
bevacizumab administration may be an effective and safe 
adjunct regimen to trabeculectomy in eyes with refractory 
glaucoma. While the blockage of angiogenesis and possible 
fibroblast modulation with anti-VEGF agent may provide 
some benefits for glaucoma filtering surgery, adverse 
complications related to the delayed wound healing process 
may also be associated. Basic research and randomized, 
controlled long-term clinical studies are required to pro-
vide further knowledge regarding the mechanism and 
application of bevacizumab as an adjunct treatment to 
trabeculectomy.
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